Skip to main content
Official Website of Stem Cell Mexico – Since 2002
Stem Cell Therapy Mexico

Does stem cell therapy cure Degenerative Disc Disease?

No. Stem cell therapy does not cure degenerative disc disease (DDD). Disc degeneration is a gradual, largely age-related process, and no current treatment, including cell therapy, has been shown to restore a degenerated disc to its original structure.

Free Consultation
Lumbar spine location on a neutral human figure

What research suggests is that mesenchymal stem cells (MSCs) injected into the disc may reduce pain and improve function in some people with chronic low back pain from disc degeneration. A 2026 meta-analysis of seven randomized trials found greater pain reduction with intradiscal MSCs than with controls, while a large European placebo-controlled trial, RESPINE, found that patients improved in both the cell and placebo groups at 12 months. At Stem Cell Mexico, spine protocols use only allogeneic MSCs from Wharton's jelly of the umbilical cord, applied with image guidance as part of a plan that includes exercise and rehabilitation. Results vary between patients.

This guide explains what DDD is, why "cure" is not a realistic goal, what the evidence shows and how cell therapy fits with proven care for back pain.

What degenerative disc disease is

The intervertebral discs are cushions between the vertebrae. Each disc has a soft, gel-like center (the nucleus pulposus) surrounded by a tough outer ring (the annulus fibrosus). Discs absorb shock and allow the spine to bend and twist.

With age, discs lose water and proteins, become thinner and less flexible, and may develop small tears in the outer ring. This process, called disc degeneration, is extremely common: imaging studies show signs of it in many adults who have no back pain at all. The term "degenerative disc disease" is used when degeneration is thought to be a source of symptoms, such as:

  • Chronic low back or neck pain, often worse with sitting, bending or lifting.
  • Episodes of more severe pain.
  • Pain that radiates to the buttocks or legs when a disc bulges or herniates and irritates a nerve.

Despite its name, DDD is not always progressive in terms of pain. Many people's symptoms improve over time, even as imaging changes persist.

This disconnect between imaging and pain is important: an MRI that shows degenerated discs does not by itself explain why someone hurts, and an MRI that looks unchanged after treatment does not mean the person has not improved.

Why a cure is not realistic

The disc has very limited capacity to repair itself. It has almost no blood supply, so nutrients and oxygen reach its cells slowly, and the number of living cells inside the nucleus decreases with age. Once the disc has lost height and its internal structure has changed, these changes are not reversed by any current treatment.

In addition, back pain is rarely caused by the disc alone. Facet joints, sacroiliac joints, muscles, ligaments, nerves, posture, physical conditioning, sleep, stress and mood all contribute. Even if a treatment could fully repair a disc, other sources of pain might remain. This is why the goal of DDD care is to reduce pain, improve function and help people stay active, rather than to "cure" the spine.

What MSCs may do in the disc

Researchers are interested in MSCs for DDD because they may:

  • Reduce inflammation inside and around the degenerated disc.
  • Support the remaining disc cells through trophic signaling.
  • Influence the production of matrix proteins that help the disc retain water.
  • Modulate pain-related signaling.

These effects are mostly demonstrated in laboratory and animal studies. Some human studies have reported changes in disc hydration on MRI in some patients, but consistent restoration of disc structure has not been shown.

What the evidence shows

Meta-analysis of randomized trials (2026)

A systematic review and meta-analysis published in the Asian Spine Journal analyzed seven randomized controlled trials with 594 patients with chronic low back pain from DDD. Intradiscal MSC injection was associated with greater pain reduction than control, with benefits that became more evident at 12 to 36 months, along with improvements in disability scores. Adverse events were similar between groups.

RESPINE trial (2024)

A multicenter, randomized, placebo-controlled trial published in the Annals of the Rheumatic Diseases treated 114 patients with chronic low back pain with a single intradiscal injection of allogeneic bone-marrow-derived MSCs or a sham procedure. At 12 months, most patients improved in both groups (74% with MSCs and 69% with placebo). The procedure was safe, with no serious treatment-related adverse events. The high response in the placebo group shows how much back pain can improve with time and expectation, and why controlled trials are essential.

What this means

Some trials and pooled analyses suggest a benefit in pain and function, while a well-designed trial found no significant difference from placebo. Cell type, dose, patient selection and how pain is measured may explain some of these differences. Cell therapy for DDD is therefore a complementary option, with results that vary between individuals.

Proven care for back pain from DDD

The NICE guideline on low back pain and sciatica (NG59) emphasizes:

  • Exercise programs, including group exercise, tailored to the person's needs.
  • Manual therapy and psychological approaches, such as cognitive behavioral therapy, as part of a combined program.
  • Medications such as anti-inflammatory drugs for short periods, when appropriate.
  • Staying active and returning to normal activities as soon as possible.
  • Surgery only in selected cases, such as nerve compression that does not improve.

Notably, NICE advises against offering spinal injections for low back pain in general, and MSC injections are not part of its recommendations. This means cell therapy, when considered, should be added to an active program, not used instead of it.

When back pain needs urgent attention

Seek medical care promptly if back pain comes with loss of bladder or bowel control, numbness in the groin area, progressive leg weakness, fever, unexplained weight loss or a history of cancer. These can be signs of conditions that need urgent diagnosis and treatment.

How Stem Cell Mexico approaches DDD

  • Cells: allogeneic MSCs from Wharton's jelly of donated umbilical cords, obtained after healthy, full-term births with informed consent and donor screening. No autologous cells or other cell sources are used.
  • Laboratory: produced in a COFEPRIS-licensed laboratory under Good Manufacturing Practice standards, with quality and safety testing before release.
  • Evaluation: review of MRI, clinical history and examination to identify the likely sources of pain.
  • Application: depending on the findings, injection into the disc, facet joints, sacroiliac joints or surrounding tissues with image guidance.
  • Rehabilitation: an exercise and activity plan after treatment.

A COFEPRIS license authorizes the facility and laboratory to operate.

Safety

In clinical trials, intradiscal MSC injections have shown a safety profile similar to control procedures. Possible risks include temporary increase in back pain, and, rarely, disc infection (discitis), bleeding or nerve irritation. No treatment is free of risk, which is why sterile technique and image guidance are essential.

Who may be a candidate

Studies of intradiscal cell therapy have generally included people who:

  • Have had chronic low back pain for at least six months.
  • Have MRI findings consistent with disc degeneration at one or two levels, without severe collapse of the disc.
  • Have not improved enough with a structured program of exercise, physical therapy and medications.
  • Do not have nerve compression that requires surgery, spinal instability, fractures, infection or tumors.

People with severe disc collapse, multiple degenerated levels, significant spinal stenosis or prior spinal fusion at the treated level are less likely to be suitable. Adults who are active in their rehabilitation and have realistic expectations are the best candidates for any spine procedure.

Warning signs when comparing clinics

Be cautious if a clinic:

  • Promises to regrow or "rehydrate" your discs.
  • Says you will avoid surgery for certain.
  • Does not review your MRI or examine you before recommending treatment.
  • Performs spine injections without image guidance.
  • Says the treatment is risk-free.

What our patients usually receive

Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:

  • 20 to 40 million Wharton's jelly MSCs per treated area, applied by direct injection with ultrasound guidance, or fluoroscopy guidance for the spine.
  • Platelet-rich plasma (PRP) in many plans, applied together with the cells.
  • One night at our facilities with nursing and medical monitoring.
  • Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
  • Your recent imaging: an MRI of the area no older than three months is requested; if yours is older, a new one can be scheduled in Tijuana on your arrival day.

Based on what patients tell us, many begin to notice improvement within a few days to a few weeks after the application, while others improve more gradually over the following months. Our team stays in contact after treatment to follow your progress and decide whether a second application or a PRP session could help.

Questions to ask during your evaluation

  • Is my pain likely to come from the disc, or from other structures?
  • What results are realistic for my case?
  • Which structures will be treated, and with what image guidance?
  • What rehabilitation should I follow afterward?
  • What are the possible risks in my situation?

Bottom line

Stem cell therapy does not cure degenerative disc disease. Some randomized trials and a 2026 meta-analysis suggest intradiscal MSCs may reduce pain and improve function, while in a large placebo-controlled trial patients improved in both groups. At Stem Cell Mexico, Wharton's jelly MSCs are offered as a complement to exercise and rehabilitation, not as a replacement. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your back condition, goals and medical history.

References

  1. Rahyussalim et al. Intradiscal mesenchymal stem cell therapy for degenerative disc disease: a systematic review and meta-analysis of randomized trials. Asian Spine Journal, 2026 (opens in a new tab)
  2. RESPINE consortium. Allogenic bone marrow-derived mesenchymal stromal cell-based therapy for patients with chronic low back pain: a prospective, multicentre, randomised placebo controlled trial (RESPINE study). Annals of the Rheumatic Diseases, 2024 (opens in a new tab)
  3. NICE guideline NG59: Low back pain and sciatica in over 16s, assessment and management (opens in a new tab)
  4. Caplan H, Olson SD, Cox CS Jr et al. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Frontiers in Immunology, 2019 (opens in a new tab)

Request your medical evaluation

A clearer path starts here.

Tell us a little about yourself. We’ll help you understand the next step.

Vania, patient coordinator at Stem Cell Mexico

Vania, our patient coordinator

Your questions. Your travel plans.
A real person to help.

Talk to Vania on WhatsApp (opens in a new tab)

What happens next?

  1. Your advisor contacts you.
  2. We explain the medical review.
  3. You explore your options.

Call +1 800 646 0290

Let’s begin with you.

Your inquiry starts a conversation. Treatment requires medical evaluation.

Vania · Patient Advisor

Start my free evaluation
Free Consultation